With trading volumes back on the upswing, it's going to be a while before Goldman's money and generosity run dry.
Morgan Stanley has grown in market share in the trading business, and there's no sign that momentum is waning.
Bristol-Myers Squibb once showed interest in Shire. With AbbVie out of the way, could deal talks between Bristol-Myers and Shire resume? Here's why a Bristol-Myers and Shire deal makes sense.
Morgan Stanley's wealth management business is still making investors rich.
BB&T shares are going to trade in a tight range until the company shows it can produce enough of a return from the money it has spent on acquisitions.
With a return on equity that tops JPMorgan and Morgan Stanley's, Goldman Sachs hasn't forgotten how to make money.
Bank of America's stock has become too expensive, and savvy investors will look to put their money elsewhere in the banking sector.
The bank's diligent cost-control measures coupled with a potential rise in interest rates make PNC one of the names to watch over the next 12 to 18 months.
Given the bank's long-term earnings growth potential and improved credit quality, these shares are heading toward $65 to $70 in the next 12 to 18 months.
Citigroup has no peer when it comes to potential stock gains in the next 12 to 18 months.